Analysts Conflicted on These Healthcare Names: Replimune Group (REPL), Minerva Surgical (UTRS) and Nektar Therapeutics (NKTR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Replimune Group (REPL – Research Report), Minerva Surgical (UTRS – Research Report) and Nektar Therapeutics (NKTR – Research Report).

Replimune Group (REPL)

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Replimune Group on August 26 and set a price target of $33.00. The company’s shares closed last Friday at $19.17.

According to TipRanks.com, Rama is a 3-star analyst with an average return of 1.6% and a 44.9% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Springworks Therapeutics, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $43.25, implying a 108.6% upside from current levels. In a report issued on August 16, Piper Sandler also maintained a Buy rating on the stock with a $43.00 price target.

See the top stocks recommended by analysts >>

Minerva Surgical (UTRS)

J.P. Morgan analyst Robbie Marcus upgraded Minerva Surgical to Buy yesterday. The company’s shares closed last Friday at $1.77, close to its 52-week low of $1.61.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 6.9% and a 45.7% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Zimmer Biomet Holdings, and Baxter International.

Minerva Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.

Nektar Therapeutics (NKTR)

Nektar Therapeutics received a Hold rating from J.P. Morgan analyst Jessica Fye yesterday. The company’s shares closed last Friday at $4.38, close to its 52-week low of $3.02.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 8.2% and a 51.2% success rate. Fye covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Intra-Cellular Therapies.

Nektar Therapeutics has an analyst consensus of Hold, with a price target consensus of $4.93.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on REPL:

• Analysts’ Top Materials Picks: Ball (BALL), Elanco Animal Health (ELAN)
• Analysts Offer Insights on Consumer Goods Companies: iRobot (IRBT), Foot Locker (FL) and Hyzon Motors (HYZN)
• Analysts Offer Insights on Technology Companies: BAE Systems (OtherBAESF), Marvell (MRVL) and Health Catalyst (HCAT)
• Positive Report for Singular Genomics Systems (OMIC) from J.P. Morgan
• J.P. Morgan upgrades Invitae (NVTA) to a Hold